Download as PDF CMS Releases CY 2023 MPFS Proposed Rule On July 7, the Centers for Medicare and Medicaid Services (CMS) issued the Calendar Year (CY) 2023 Medicare Physician Fee Schedule (MPFS) proposed rule. The proposed CY 2023 MPFS conversion factor is $33.08, a decrease of $1.53 to the CY 2022 MPFS conversion factor of …
Read MoreBy: Bri Driggers, Juan Arredondo The mark of success for a revenue cycle is receiving full and timely reimbursement. But the question is, “how do you make sure you’re fully reimbursed and on time?” The answer may seem complex, but it comes down to accurate medical coding. Medical billing and coding are two of the …
Read MoreBy: Ron DiGiaimo, MBA, FACHE, Dr. Michael L. Steinberg, MD, FASTRO, FACR, Ben Adams, Bri Driggers Cancer growth and cancer care have never stopped in the world of Oncology and the COVID-19 pandemic. However, within the wider scope of healthcare, fast legislative and operation reform and comparisons to previous pandemic public reactions such as the …
Read MoreBy: Ron DiGiaimo, MBA, FACHE, Dr. Louis Potters, MD, FACR, FASTRO, FABS, Ben Adams, Bri Driggers Cancer growth and cancer care have never stopped in the world of Oncology and the COVID-19 pandemic. Hospitals and cancer centers face unique challenges, adapting quickly to ensure the safety of cancer patients at heightened risk for COVID-19. Across …
Read MoreDownload as PDF New Model for Cancer Care Announced On June 27, 2022, a new voluntary model was announced to improve cancer care for Medicare beneficiaries. The Centers for Medicare and Medicaid Services’ (CMS) Center for Medicare and Medicaid Innovation Center announced the newly designed Enhancing Oncology Model (EOM). CMS cites the central goal of …
Read MoreBy: Ron DiGiaimo, MBA, FACHE, Dr. Catheryn Yashar, MD, FACRO, FABS, FACR, FASTRO, Ben Adams, Bri Driggers Cancer growth and cancer care have never stopped in the world of oncology and the COVID-19 global pandemic. Hospitals and cancer centers faced unique challenges and were forced to adapt quickly to ensure the safety of cancer patients, …
Read MoreDownload as PDF Biosimilars With the ever-rising cost of cancer treatments, biosimilars provide opportunities for treatment to patients with limited access to patented originator biotherapeutics. Biosimilar refers to those biotherapeutic produces which are extremely similar in quality, safety, and efficacy to an existing licensed originator product but are not considered identical chemical copies. The International …
Read MoreDownload as PDF RO Model Delayed, Again Since its initial intended implementation date of January 1, 2021, the Radiation Oncology (RO) Model has experienced a multitude of delays. Most recently, on April 6, 2022, CMS proposed another delay to the start of the RO Model to a yet to be determined date that will be …
Read MoreDownload as PDF FDA Released New Cancer Trial Guidance Following the relaunch of the White House’s Cancer Moonshot initiative, the U.S. Food and Drug Administration (FDA) issued new guidance for cancer trials to align with the goals drawn up within the initiative. The FDA responded to the Moonshot initiative’s goals of reducing the cancer death …
Read MoreWe are proud to announce our partnership with Relias, a trusted partner to more than 11,000 healthcare organizations and over four million caregivers. We will work to help grow education and training products. Learn more by reading their press release here.
Read More